Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18814945 | 1.00 | CYP3A4 (0.47) | CYP3A4CYP1A2CYP2C9TSHRABCB11 | |
| SCHEMBL20103745 | 0.86 | CYP3A4 (0.61) | CYP3A4CYP1A2CYP2C9TSHRABCB11 | |
| SCHEMBL18477543 | 0.86 | CYP3A4 (0.54) | CYP3A4CYP1A2CYP2C9TSHRABCB11 | |
| SCHEMBL7733840 | 0.84 | CYP3A4 (0.63) | CYP3A4CYP1A2CYP2C9TSHRABCB11 | |
| SCHEMBL9013443 | 0.84 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2C9TSHRABCB11 | |
| SCHEMBL23225661 | 0.82 | CYP3A4 (0.61) | CYP3A4CYP1A2CYP2C9TSHRABCB11 | |
| SCHEMBL11858247 | 0.82 | CYP3A4 (0.66) | CYP3A4CYP1A2CYP2C9TSHRABCB11 | |
| SCHEMBL23225659 | 0.82 | CYP3A4 (0.66) | CYP3A4CYP1A2CYP2C9TSHRABCB11 | |
| SCHEMBL14709851 | 0.81 | OPRM1 (0.46) | CYP3A4CYP1A2CYP2C9TSHRABCB11 | |
| SCHEMBL13688355 | 0.80 | CYP3A4 (0.37) | CYP3A4CYP1A2CYP2C9TSHRABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544141-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190077800-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-10093669-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9518057-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518057-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077800-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | CYP3A4 953/4885CYP1A2 1092/4885CYP2C9 2552/4885 |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | CYP3A4 953/4885CYP1A2 1092/4885CYP2C9 2552/4885 |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | CYP3A4 953/4885CYP1A2 1092/4885CYP2C9 2552/4885 |
| US-10544141-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | CYP3A4 953/4885CYP1A2 1092/4885CYP2C9 2552/4885 |
| US-10093669-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | CYP3A4 953/4885CYP1A2 1092/4885CYP2C9 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.